Protagonist Halts Clinical Trial of PTG-100 for UC After Analysis Finds Study Futile

Protagonist Halts Clinical Trial of PTG-100 for UC After Analysis Finds Study Futile
A Phase 2b trial of PTG-100, an investigative therapy for moderate-to-severe ulcerative colitis (UC), has been discontinued after an interim analysis deemed the study futile, according to Protagonist Therapeutics. The randomized, double-blind Phase 2b PROPEL trial (NCT02895100), initiated in 2016, was evaluating the safety and efficacy of three daily doses of oral PTG-100 (150 mg, 300 mg, or 900 mg), for 12 weeks in people with moderate-to-severe UC. The study's main goal (primary endpoint) was the proportion of people UC patie
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *